{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:07:51Z","timestamp":1778828871963,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.7759\/cureus.108868","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:13:53Z","timestamp":1778825633000},"source":"Crossref","is-referenced-by-count":0,"title":["Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System"],"prefix":"10.7759","author":[{"given":"Alisher","family":"Makhmutov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning P","year":"2025","unstructured":"Berning P, Adhikari R, Schroer AE, Jelwan YA, Razavi AC, Blaha MJ, Dzaye O. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open. 2025, 8:e2457232. 10.1001\/jamanetworkopen.2024.57232","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae156","article-title":"Euglycemic ketoacidosis from semaglutide in a patient without diabetes","volume":"2","author":"Sood N","year":"2024","unstructured":"Sood N, Bansal O, Garg R, Hoskote A. Euglycemic ketoacidosis from semaglutide in a patient without diabetes. JCEM Case Rep. 2024, 2:luae156. 10.1210\/jcemcr\/luae156","journal-title":"JCEM Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal PM","year":"2024","unstructured":"Iqbal PM, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024, 11:004357. 10.12890\/2024_004357","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01749-x","article-title":"GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review","volume":"49","author":"Sood N","year":"2025","unstructured":"Sood N, Buddhavarapu V, Garg R. GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review. Int J Obes (Lond). 2025, 49:977-9. 10.1038\/s41366-025-01749-x","journal-title":"Int J Obes (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.92a.24075","article-title":"Classic diabetic ketoacidosis and the euglycemic variant: something old, something new","volume":"92","author":"Mehta AE","year":"2025","unstructured":"Mehta AE, Zimmerman R. Classic diabetic ketoacidosis and the euglycemic variant: something old, something new. Cleve Clin J Med. 2025, 92:33-9. 10.3949\/ccjm.92a.24075","journal-title":"Cleve Clin J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller TD","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al.. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019, 30:72-130. 10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000517305","article-title":"Starvation ketosis and the kidney","volume":"52","author":"Palmer BF","year":"2021","unstructured":"Palmer BF, Clegg DJ. Starvation ketosis and the kidney. Am J Nephrol. 2021, 52:467-78. 10.1159\/000517305","journal-title":"Am J Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09073-2","article-title":"Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients: a narrative review","volume":"40","author":"Garg R","year":"2025","unstructured":"Garg R, Sood N, Bansal O, Hoskote A. Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients: a narrative review. J Gen Intern Med. 2025, 40:437-42. 10.1007\/s11606-024-09073-2","journal-title":"J Gen Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang Z","year":"2022","unstructured":"Yang Z, Yu M, Mei M, Chen C, Lv Y, Xiang L, Li R. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2022, 32:504-10. 10.1016\/j.numecd.2021.10.003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020214","article-title":"Diabetic ketoacidosis and the use of new hypoglycemic groups: real-world evidence utilizing the Food and Drug Administration Adverse Event Reporting System","volume":"18","author":"Thaibah HA","year":"2025","unstructured":"Thaibah HA, Banji OJ, Banji D, Alshammari TM. Diabetic ketoacidosis and the use of new hypoglycemic groups: real-world evidence utilizing the Food and Drug Administration Adverse Event Reporting System. Pharmaceuticals (Basel). 2025, 18:214. 10.3390\/ph18020214","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-026-01916-5","article-title":"Managing metabolic risks in coronary artery disease: a scoping review of recent clinical and therapeutic evidence","volume":"25","author":"Gudla SS","year":"2026","unstructured":"Gudla SS, Bhumireddy SK, Vadaga AK, Nandula MS. Managing metabolic risks in coronary artery disease: a scoping review of recent clinical and therapeutic evidence. J Diabetes Metab Disord. 2026, 25:118. 10.1007\/s40200-026-01916-5","journal-title":"J Diabetes Metab Disord"},{"key":"ref14","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). (2024). Accessed: April 17, 2026: https:\/\/www.fda.gov\/drugs\/surveillance\/fda-adverse-event-reporting-system-faers."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek EP","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002, 11:3-10. 10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487988-ketoacidosis-risk-in-non-diabetic-patients-using-semaglutide-versus-tirzepatide-for-obesity-a-disproportionality-analysis-of-the-fda-adverse-event-reporting-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:14:00Z","timestamp":1778825640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487988-ketoacidosis-risk-in-non-diabetic-patients-using-semaglutide-versus-tirzepatide-for-obesity-a-disproportionality-analysis-of-the-fda-adverse-event-reporting-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.108868","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}